I was under the impression that non-squamous (the patients that are being screen for only inclusion into the MARQUEE) are high c-Met, no?
In retrospect, it does seem incredibly silly that they would not have tested specifically for high c-Met NSCLC patients ONLY (and not simply going for an all-comers type of non-squam NSCLC) using a diagnostic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.